United Therapeutics UTHR EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by United Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about United Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is United Therapeutics's EPS (diluted)?
- United Therapeutics (UTHR) reported EPS (diluted) of $5.82 in Q1 2026.
- How has United Therapeutics's EPS (diluted) changed year-over-year?
- United Therapeutics's EPS (diluted) decreased by 12.2% year-over-year, from $6.63 to $5.82.
- What is the long-term trend for United Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), United Therapeutics's EPS (diluted) has grown at a 29.2% compound annual growth rate (CAGR), from $10.02 to $27.89.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.